Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-B-K ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis


Creative Commons License

Ozden F. O. , Sakallioglu E. E. , Demir E. , Bilgici B., Tuncel O. K. , Gokosmanoglu F., ...More

JOURNAL OF ORAL SCIENCE, vol.59, no.1, pp.147-155, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.2334/josnusd.16-0241
  • Title of Journal : JOURNAL OF ORAL SCIENCE
  • Page Numbers: pp.147-155
  • Keywords: bisphosphonate, non-surgical periodontal treatment, osteoporosis, RANKL, OPG, periodontitis, BONE-MINERAL DENSITY, RECEPTOR ACTIVATOR, ZOLEDRONIC ACID, RELATIVE RATIO, DISEASE, RISEDRONATE, WOMEN, SERUM, EXPRESSION, INFLAMMATION

Abstract

Osteoporosis and periodontal disease are linked by an altered receptor activator of nuclear factor B-K ligand and osteoprotegerin ratio (RANKL/OPG), and medical treatment with bisphosphonate (BP) may help control these molecules. The effect of BP on clinical findings and gingival crevicular fluid (GCF) values of RANKL and OPG using enzyme-linked immunosorbent assays was evaluated in postmenopausal women; 13 patients with both chronic periodontitis and osteoporosis (group A), 12 systemically healthy patients with chronic periodontitis (group B), 12 periodontally healthy patients with osteoporosis (group C), and 10 systemically and periodontally healthy individuals (group D). Recordings were repeated at the end of months 1, 6, and 12 in groups A, B, and C. At the baseline, groups A and B exhibited the lowest OPG values (P < 0.05). After periodontal treatment, OPG values were markedly increased at the end of 6th month in group A and 12th month in group B (P < 0.008). There was no significant difference in GCF RANKL values among groups (P > 0.05) or during the observation period (P > 0.008). The use of BP may be effective in preventing periodontal breakdown by controlling the levels of these markers in osteoporosis as an adjunct to periodontal treatment.